Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Financial toxicity in hematological malignancies: a systematic review.
Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR. Ouchveridze E, et al. Blood Cancer J. 2022 Apr 22;12(4):74. doi: 10.1038/s41408-022-00671-z. Blood Cancer J. 2022. PMID: 35459862 Free PMC article.
Value in Myeloma Care: Myth or Reality.
Ouchveridze E, Berger K, Mohyuddin GR. Ouchveridze E, et al. Curr Hematol Malig Rep. 2022 Dec;17(6):206-216. doi: 10.1007/s11899-022-00669-1. Epub 2022 Aug 30. Curr Hematol Malig Rep. 2022. PMID: 36040675 Review.
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma.
Afrough A, Atrash S, Paul B, Ouchveridze E, Ahmed N, Mahmoudjafari Z, Bashir A, Alkharabsheh O, Hashmi H, Abdallah AO. Afrough A, et al. Among authors: ouchveridze e. Cancers (Basel). 2023 Oct 9;15(19):4894. doi: 10.3390/cancers15194894. Cancers (Basel). 2023. PMID: 37835587 Free PMC article.
Subgroups and precision in myeloma.
Ouchveridze E, Booth C, Mohyuddin GR. Ouchveridze E, et al. J Cancer Policy. 2023 Mar;35:100407. doi: 10.1016/j.jcpo.2023.100407. Epub 2023 Jan 22. J Cancer Policy. 2023. PMID: 36696948 No abstract available.